WJ35435

WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC (in particular HDAC1 and HDAC6) and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer[1].

Product Specifications

CAS Number

[1620054-84-3]

UNSPSC

12352005

Target

Apoptosis; HDAC; Topoisomerase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/wj35435.html

Smiles

O=C(C1=CC=CC2=CC3=C(N=C21)C=CC=C3)NCCCCCC(NO)=O

Molecular Formula

C20H21N3O3

Molecular Weight

351.40

References & Citations

[1]Yu C C, et al. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I[J]. Biochemical pharmacology, 2014, 90 (3) : 320-330.